ClinicalTrials.gg
RecruitingNCT03713879Updated Oct 21, 2026

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

A Phase 3 interventional study of pancreatic stenting and Indomethacin in Post ERCP Pancreatitis, sponsored by Chinese University of Hong Kong. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Chinese University of Hong Kong · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2019; still recruiting 7 years 8 months later.
Updated Oct 21, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,734
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing indomethacin in Pancreatitis — 6 open to participants now, 6 under way, 1 of them phase 3. Indomethacin · Pancreatitis.

Planned enrollment
3rd of 20
1,734 · median 492
Started
2019
the only one that year
Phase 3
6 of 20
1 open now
Registered
11th of 20
by date
Lead sponsor
1 of 20
Chinese University of Hong Kong

Among the 20 studies testing indomethacin in Pancreatitis, this one is the 3rd largest by planned enrollment, is the only one that started in 2019, is one of 6 in phase 3, and was the 11th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

6 of the 20 studies testing indomethacin in Pancreatitis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About indomethacin

Indomethacin: first FDA approval 1965 (INDOCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing indomethacin in Pancreatitis, or all of them as a file.
02

Study summary

Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant morbidities and occasional mortalities. The use of rectall administered indomethacin and pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The comparative effectiveness of the two methods has however not been studied. It is argued that in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS insertion however believe that mechanical decompression of the pancreatic duct is critical in the prevention of pancreatitis. The investigators propose a multi-centre randomised controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk patients in the prevention of PEP.

Read the detailed description

Background of research

Pancreatitis is the most common complication after Endoscopic retrograde cholangiopancreatography (ERCP). It occurs in approximately 5% of patients. The risk can approach 20 to 30% in those with known pre- and intra-procedural risk factors. Three in 100 patients with post ERCP pancreatitis (PEP) consequently die. The placement of pancreatic duct stent and the use of rectal administered indomethacin have both been independently shown to reduce PEP. The placement of a pancreatic duct stent has been for a long time considered the gold standard in the prophylaxis against PEP. In a meta-analysis of 8 RCTs that compared the use of pancreatic duct stents to no treatment, pancreatic duct stenting in high risk patients reduces incidence of PEP by approximately 5 fold. In a landmark study by Elmunzer et al., rectal administered indomethacin was shown to reduce PEP (52 of 307 patients,16.9% to 27 of 295 patients, 9.2%, P=0.005). In the trial, >80% received pancreatic duct stents in addition to rectal indomethacin. Overall there have been 7 RCTs on the use of rectal indomethacin all showing benefits with its use, 3 with PDS and 4 without. In the literature, there has been no direct comparison between the use of rectal indomethacin alone and insertion of PDS. In a secondary analysis of the trial by Elmunzer et al., PEP following the use of rectal indomethacin alone was less compared with the placement of PDS. In a meta-analysis by Akbar et al. pooling 29 studies (22 PDS and 7 indomethacin), the use of rectal indomethacin alone was associated with fewer PEP when compared to insertion of PDS on an indirect comparison using network metaanalysis (OR 0.48, 95%CI 0.26-0.87). The more favorable results with rectal indomethacin alone raised the question if PDS insertion is necessary. Furthermore, in another secondary analysis, patients after failed PDS insertion had a 34.7% rate of pancreatitis. In contrary, the rate of pancreatitis was 16.4% in those after successful PDS and 12.1% after no attempt at PDS insertion. The SVI (stent versus indomethacin) trial (NCT024762279) by the US cooperative for Outcomes Research in Endoscopy (USCORE) group is an ongoing non-inferiority trial that compares indomethacin alone to the combination of indomethacin and PDS in 1430 high risk patients with the primary outcome of pancreatitis. The trial tests the hypothesis that PDS is no longer necessary in the context of rectal indomethacin.

The rationale for the trial has been based on the secondary analysis of the Elmunzer trial and the network analysis aforementioned.

The investigators argue that the relative merits of rectal indomethacin and PDS placement have not been established. There may have been substantial difference in the baseline risks between the trials using either rectal indomethacin and PDS placement alone. The small number of RCTs over the use of rectal indomethacin may have overestimated its beneficial effect especially among patients at lower risk of PEP. A direct comparison in the form of a RCT to compare effectiveness of both treatment modalities is required. The insertion of PDS may continue to be important in patients contraindicated for the use of NSAIDs.

Research plan and methodology The investigators hypothesize that rectal administration of indomethacin is not inferior to placement of a pancreatic duct stent in the prevention of pancreatitis after ERCP in high risk patients. In patients randomised to receive pancreatic duct stents, the investigators sought to determine the success rate with PDS insertion and outcomes following successful or unsuccessful PDS insertion. In addition, the investigators analyse possible factors to PEP in both cohorts of patients on either indomethacin or PDS.

03

Conditions studied

  • Post ERCP Pancreatitis

Browse trials for

Keywords

  • post ERCP panceatitis
  • rectal indomethacin
  • pancreatic stents
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

presence of one of the following risk factors for Post ERCP Pancreatitis

  1. sphincter of Oddi dysfunction
  2. history of PEP, pancreatic instrumentation or sphincterotomy, precut sphincterotomy,
  3. difficult cannulation defined by >5 cannulation attempts
  4. the use of double wire technique in bile duct access
  5. at least 2 of the followings including i) female age\<50 ii) 3 pancreatograms iii) acinarization (contrast injection to tail fo pancreas). iv) normal ; v)guidewire to the tail of pancreas or secondary branches.

Exclusion criteria

Exclusion Criteria:

  • patients intended for pancreatic stenting e.g. those with pancreatic duct strictures, ampullectomy,
  • without informed consents from patient or next of kin
  • age \<18
  • pregnant or lactating women
  • patients with altered anatomy except except Billroth I and II gastrectomy
  • to the use of NSAIDs such as those with active gastrointestinal bleeding, renal failure (serum creatinine > 140)
  • known NSAID allergy
  • incipient heart failure.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,734 participants (estimated)

Study arms

  • Experimental
    indomethacin

    rectal indomethacin 100 mg to be administered before or after ERCP

    Drug: Indomethacin

  • Experimental
    pancreatic stenting

    a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025" or .035" wire)

    Device: pancreatic stenting

  • Experimental
    indomethacin plus pancreatic stenting

    \[rectal indomethacin 100 mg to be administered before or after ERCP\] plus \[a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025" or .035" wire\]

    Device: pancreatic stenting · Drug: Indomethacin

Interventions

  • Devicepancreatic stenting

    a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025" or .035" wire)

  • rectally administered indomethacin before or after ERCP

    Also known as: indocid

06

What researchers measure

Primary outcomes

  1. post-ERCP pancreatitis

    Percentage of Participants with post ERCP pancreatitis

    Time frame: 30 days

  2. high severity of post-ERCP pancreatitis

    Percentage of Participants with high severity of post-ERCP pancreatitis using the Clavian-Dindo classification (1 / 2 / 3 / 3a / 3b / 4 / 4a/ 4b / 5)

    Time frame: 30 days

  3. pancreatitis with complications

    Percentage of Participants with pancreatitis with complications using Atlanta classification (Mild / Moderate / Severe / Critical )

    Time frame: 30 days

Secondary outcomes

  1. hospital stay

    period of hospitalisation (days)

    Time frame: 30 days

  2. endoscopic intervention due to PEP

    Percentage of Participants with endoscopic intervention due to Post ERCP pancreatitis

    Time frame: 30 days

  3. radiologic intervention due to PEP

    Percentage of Participants with radiologic intervention due to Post ERCP pancreatitis

    Time frame: 30 days

  4. surgery due to PEP

    Percentage of Participants with Surgical intervention due to Post ERCP pancreatitis

    Time frame: 30 days

07

Study locations

6 of 7 sites recruiting
  • Endoscopy centre
    Xi'an, Shaanxi 710000, China
    Recruiting
    • Yang Lin Pan, MD · Contactpanyl@fmmu.edu.cn
    • Pang Yang Lin, MD · Sub investigator
    • Kai Chun Wu, MD · Principal investigator
  • Eastern Hepatobiliary Surgery Hospital,Endoscopy centre
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
  • Endoscopy centre
    Shanghai, Shanghai Municipality 200000, China
    Not yet recruiting
  • Endoscopy centre
    Tianjin, Tianjin Municipality 300000, China
    Recruiting
    • Wen Li, MD · Contactdrliwen@126.com
    • Wen Li, MD · Principal investigator
  • Endoscopy centre
    Hangzhou, Zhejiang 310013, China
    Recruiting
    • Yun Sheng Qing, MD · Contact175260446@qq.com
    • Yun sheng Qing, MD · Principal investigator
  • Endoscopy Centre, Prince of Wales Hospital
    Hong Kong, Hong Kong, Hong Kong
    Recruiting
  • 2. Chulalongkorn University and King Chulalongkorn Memorial Hospital
    Bangkok, Thailand
    Recruiting
08

References and documents

Publications

  • Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007 Aug;102(8):1781-8. doi: 10.1111/j.1572-0241.2007.01279.x. Epub 2007 May 17. PubMed 17509029 ↗
  • Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011 Feb;73(2):275-82. doi: 10.1016/j.gie.2010.10.039. PubMed 21295641 ↗
  • Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22. doi: 10.1056/NEJMoa1111103. PubMed 22494121 ↗
  • Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91. doi: 10.1016/s0016-5085(03)00384-6. PubMed 12806612 ↗
  • Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e11-6. doi: 10.1111/j.1440-1746.2007.05096.x. Epub 2007 Aug 7. PubMed 17683501 ↗
  • Montano Loza A, Rodriguez Lomeli X, Garcia Correa JE, Davalos Cobian C, Cervantes Guevara G, Medrano Munoz F, Fuentes Orozco C, Gonzalez Ojeda A. [Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes]. Rev Esp Enferm Dig. 2007 Jun;99(6):330-6. doi: 10.4321/s1130-01082007000600005. Spanish. PubMed 17883296 ↗
  • Otsuka T, Kawazoe S, Nakashita S, Kamachi S, Oeda S, Sumida C, Akiyama T, Ario K, Fujimoto M, Tabuchi M, Noda T. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012 Aug;47(8):912-7. doi: 10.1007/s00535-012-0554-7. Epub 2012 Feb 18. PubMed 22350703 ↗
  • Katsinelos P, Fasoulas K, Paroutoglou G, Chatzimavroudis G, Beltsis A, Terzoudis S, Katsinelos T, Dimou E, Zavos C, Kaltsa A, Kountouras J. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy. 2012 Jan;44(1):53-9. doi: 10.1055/s-0031-1291440. Epub 2011 Dec 23. PubMed 22198776 ↗
  • Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007 May;102(5):978-83. doi: 10.1111/j.1572-0241.2007.01165.x. Epub 2007 Mar 13. PubMed 17355281 ↗
  • Elmunzer BJ, Higgins PD, Saini SD, Scheiman JM, Parker RA, Chak A, Romagnuolo J, Mosler P, Hayward RA, Elta GH, Korsnes SJ, Schmidt SE, Sherman S, Lehman GA, Fogel EL; United States Cooperative for Outcomes Research in Endoscopy. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol. 2013 Mar;108(3):410-5. doi: 10.1038/ajg.2012.442. Epub 2013 Jan 8. PubMed 23295278 ↗
  • Akbar A, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol. 2013 Jul;11(7):778-83. doi: 10.1016/j.cgh.2012.12.043. Epub 2013 Jan 30. PubMed 23376320 ↗
  • Choksi NS, Fogel EL, Cote GA, Romagnuolo J, Elta GH, Scheiman JM, Chak A, Mosler P, Higgins PD, Korsnes SJ, Schmidt SE, Sherman S, Lehman GA, Elmunzer BJ; United States Cooperative for Outcomes Research in Endoscopy. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. Gastrointest Endosc. 2015 Jan;81(1):150-5. doi: 10.1016/j.gie.2014.07.033. PubMed 25527053 ↗
  • Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991 May-Jun;37(3):383-93. doi: 10.1016/s0016-5107(91)70740-2. PubMed 2070995 ↗
  • Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2. PubMed 19638912 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2019 (actual). Primary completion is estimated for May 2028, 110 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2026 → May 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Oct 22, 2018
StartActual
Mar 21, 2019
Primary completionEst.
May 31, 2028was Dec 2026
CompletionEst.
Dec 31, 2028was Dec 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (4 China, 1 Hong Kong)
  • Endoscopy centre · Xi'an, China
  • Eastern Hepatobiliary Surgery Hospital,Endoscopy centre · Shanghai, China
  • Endoscopy centre · Shanghai, China
  • Endoscopy centre · Tianjin, China
  • Endoscopy Centre, Prince of Wales Hospital · Hong Kong, Hong Kong
Show 5 removed
  • Endoscopy centre · Xi'an, China
  • Eastern Hepatobiliary Surgery Hospital,Endoscopy centre · Shanghai, China
  • Endoscopy centre · Shanghai, China
  • Endoscopy centre · Tianjin, China
  • Endoscopy Centre, Prince of Wales Hospital · Hong Kong, Hong Kong
Oct 21, 2026
Primary completion
Dec 31, 2026→May 31, 2028
Oct 21, 2026
Study completion
Dec 31, 2026→Dec 31, 2028
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Endoscopy centre · Hangzhou, ChinaContact person changed (no phone or email listed)
Oct 21, 2026
Sponsor
Collaborators added: First Affiliated Hospital of Zhejiang University; collaborators removed: Zhejiang University
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    5 sites added, 5 sites removed
    Show 5 added (4 China, 1 Hong Kong)
    • Endoscopy centre · Xi'an, China
    • Eastern Hepatobiliary Surgery Hospital,Endoscopy centre · Shanghai, China
    • Endoscopy centre · Shanghai, China
    • Endoscopy centre · Tianjin, China
    • Endoscopy Centre, Prince of Wales Hospital · Hong Kong, Hong Kong
    Show 5 removed
    • Endoscopy centre · Xi'an, China
    • Eastern Hepatobiliary Surgery Hospital,Endoscopy centre · Shanghai, China
    • Endoscopy centre · Shanghai, China
    • Endoscopy centre · Tianjin, China
    • Endoscopy Centre, Prince of Wales Hospital · Hong Kong, Hong Kong
    Primary completion Dec 31, 2026→May 31, 2028
    Study completion Dec 31, 2026→Dec 31, 2028
    Sponsor Collaborators added: First Affiliated Hospital of Zhejiang University; collaborators removed: Zhejiang University
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Endoscopy centre · Hangzhou, ChinaContact person changed (no phone or email listed)
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03713879
Collaborators
Xijing Hospital, Changhai Hospital, Tianjin Union Medical Center, First Affiliated Hospital of Zhejiang University, Eastern Hepatobiliary Surgery Hospital
Responsible party
James Yun-wong Lau, MD (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Oct 22, 2018
Start date
Mar 21, 2019
Primary completion
May 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

James LAU, MD
Contact
laujyw@surgery.cuhk.edu.hk
35051411
RAYMOND TANG, MD
Contact
raymondtang@cuhk.edu.hk
35052640
James LAU, MD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indomethacin

Start the discussion